Shantha Biotechnics
| Company type | Parent Sanofi | |
|---|---|---|
| Website | Shanthabiotech.com |
Shantha Biotechnics Limited is an Indian
Shantha Biotechnics caters to major international markets including Asia-Pacific, Africa,
History
Shantha Biotechnics, Ltd. began with the initiatives of Dr.
In 2006 the European biotech major Mérieux Alliance bought a 60% stake in Shantha Biotechnics at a valuation of $175 million.[2]
In 2009, the vaccine division of French pharmacological company Sanofi Pasteur acquired the stake held by Mérieux Alliance, valuing Shantha Biotech at Euro 550 million (over Rs 3,770 crore).[3]
Over time, Sanofi acquired a further stake in Shantha Biotechnics and in 2013 acquired 100% of the company.[4]
Products
Drugs developed by Shantha include SHANVAC-B, SHANFERON, SHANKINASE, SHANPOIETIN, pediatric combination vaccines Shantetra and
Insuman cartridges project
The main object of the Insuman Cartridges Project is to produce insulin at a lower cost. It is in Medak district, Telangana. The project cost is ₹460 crore.[5]
See also
References
- ^ a b "Shantha Biotech to launch 5-in-1 pediatric vaccine – CNBC-TV18". Moneycontrol.com. Retrieved 28 September 2012.
- ^ "Sanofi-Aventis Takes Control Of Shantha Biotechnics". VCCircle. Retrieved 19 September 2015.
- ^ Somashekar Mulugu. "Business Line : Companies News : Top level changes at Shantha Biotechnics". Thehindubusinessline.com. Retrieved 28 September 2012.
- ^ "Sanofi infusing $122M to complete buy-out of Shantha Biotech and further expansion". VCCircle. Retrieved 19 September 2015.
- ^ Details: Insuman Cartridges Project